ERYZOLE Drug Patent Profile
✉ Email this page to a colleague
When do Eryzole patents expire, and what generic alternatives are available?
Eryzole is a drug marketed by Alra and is included in one NDA.
The generic ingredient in ERYZOLE is erythromycin ethylsuccinate; sulfisoxazole acetyl. There are one hundred and three drug master file entries for this compound. Additional details are available on the erythromycin ethylsuccinate; sulfisoxazole acetyl profile page.
Summary for ERYZOLE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 122 |
Formulation / Manufacturing: | see details |
DailyMed Link: | ERYZOLE at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for ERYZOLE
US Patents and Regulatory Information for ERYZOLE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Alra | ERYZOLE | erythromycin ethylsuccinate; sulfisoxazole acetyl | GRANULE;ORAL | 062758-001 | Jun 15, 1988 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |